Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
Vela-Ojeda J, Tripp-Villanueva F, Montiel-Cervantes L, Sánchez-Cortés E, Ayala-Sánchez M, Guevara-Moreno ME, García-León LD, Rosas-Cabral A, Esparza MA, González-Llaven J. Vela-Ojeda J, et al. Bone Marrow Transplant. 2000 Jun;25(11):1141-6. doi: 10.1038/sj.bmt.1702426. Bone Marrow Transplant. 2000. PMID: 10849526 Clinical Trial.
Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia.
Vela-Ojeda J, García-Ruiz Esparza MA, Rosas-Cabral A, Padilla-González Y, García-Chávez J, Tripp-Villanueva F, Sánchez-Cortés E, Ayala-Sánchez M, García-León LD, Montiel-Cervantes L, Rubio-Borja ME. Vela-Ojeda J, et al. Ann Hematol. 2002 Jul;81(7):362-7. doi: 10.1007/s00277-002-0480-5. Epub 2002 Jun 25. Ann Hematol. 2002. PMID: 12185504 Clinical Trial.
Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.
Vela-Ojeda J, García-Ruiz Esparza MA, Reyes-Maldonado E, Jiménez-Zamudio L, Moreno-Lafont M, García-Latorre E, Ramírez-Sanjuan E, Montiel-Cervantes L, Tripp-Villanueva F, García-León LD, Ayala-Sánchez M, Rosas-Cabral A, Aviña-Zubieta JA, Galindo-Rodríguez G, Vadillo-Buenfil M, Salazar-Exaire D. Vela-Ojeda J, et al. Ann Hematol. 2004 May;83(5):295-301. doi: 10.1007/s00277-003-0822-y. Epub 2003 Dec 5. Ann Hematol. 2004. PMID: 15060749
Allogeneic peripheral blood stem cell transplantation using reduced intensity versus myeloablative conditioning regimens for the treatment of leukemia.
Vela-Ojeda J, García-Ruiz Esparza MA, Tripp-Villanueva F, Ayala-Sánchez M, Delgado-Lamas JL, Garcés-Ruiz O, Rubio-Jurado B, Montiel-Cervantes L, Sánchez-Cortés E, García-Chavez J, Xolotl-Castillo M, Rosas-Cabral A, Salazar-Exaire D, Galindo-Rodríguez G, Aviña-Zubieta A. Vela-Ojeda J, et al. Stem Cells Dev. 2004 Oct;13(5):571-9. doi: 10.1089/scd.2004.13.571. Stem Cells Dev. 2004. PMID: 15588514
CD4+ CD25+ lymphocyte and dendritic cell mobilization with intermediate doses of recombinant human granulocyte colony-stimulating factor in healthy donors.
Vela-Ojeda J, Esparza MA, Reyes-Maldonado E, Jiménez-Zamudio L, García-Latorre E, Moreno-Lafont M, Estrada-García I, Mayani H, Montiel-Cervantes L, Tripp-Villanueva F, Ayala-Sánchez M, García-León LD, Borbolla-Escoboza JR. Vela-Ojeda J, et al. Stem Cells Dev. 2005 Jun;14(3):310-6. doi: 10.1089/scd.2005.14.310. Stem Cells Dev. 2005. PMID: 15969626
Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation.
Vela-Ojeda J, García-Ruiz Esparza MA, Reyes-Maldonado E, Jiménez-Zamudio L, García-Latorre E, Moreno-Lafont M, Estrada-García I, Montiel-Cervantes L, Tripp-Villanueva F, Ayala-Sánchez M, García-León LD, Borbolla-Escoboza JR, Mayani H. Vela-Ojeda J, et al. Ann Hematol. 2006 Feb;85(2):113-20. doi: 10.1007/s00277-005-0037-5. Epub 2005 Nov 26. Ann Hematol. 2006. PMID: 16311734
Peripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin's lymphoma and multiple myeloma.
Vela-Ojeda J, García-Ruiz Esparza MA, Reyes-Maldonado E, Jiménez-Zamudio L, García-Latorre E, Moreno-Lafont M, Estrada-García I, Mayani H, Montiel-Cervantes L, Tripp-Villanueva F, Ayala-Sánchez M, García-León LD, Borbolla-Escoboza JR. Vela-Ojeda J, et al. Ann Hematol. 2006 May;85(5):308-14. doi: 10.1007/s00277-006-0090-8. Epub 2006 Mar 7. Ann Hematol. 2006. PMID: 16525786 Clinical Trial.
74 results